Research ArticleArticle
Bioethics in Practice: Considerations for Stopping a Clinical Trial Early
Richard E. Deichmann, Marie Krousel-Wood and Joseph Breault
Ochsner Journal September 2016, 16 (3) 197-198;
Richard E. Deichmann
1Department of Internal Medicine, Ochsner Clinic Foundation, New Orleans, LA
2The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA
MDMarie Krousel-Wood
3Department of Medicine, Tulane University School of Medicine, Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA and Research Division, Ochsner Clinic Foundation, New Orleans, LA
MD, MSPHJoseph Breault
2The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA
4Department of Family Medicine and Institutional Review Board Chair, Ochsner Clinic Foundation, New Orleans, LA
MDREFERENCES
- ↵
- Wright JT Jr.,
- Williamson JD,
- Whelton PK
- ↵
- Bassler D,
- Briel M,
- Montori VM,
- et al.
- Korn EL,
- Freidlin B,
- Mooney M.
- Ellenberg SS,
- DeMets DL,
- Fleming TR.
- Goodman S,
- Berry D,
- Wittes J.
- ↵
- Korn EL,
- Freidlin B,
- Mooney M.
- ↵
- Dahlöf B,
- Sever PS,
- Poulter NR,
- et al.
- ↵
- Zannad F,
- McMurray JJ,
- Krum H,
- et al.
- ↵
- Cleophas TJ,
- Zwinderman AH.
- ↵
- Pocock SJ.
- ↵US Food and Drug Administration Institutional Review Boards. FDA: 21 CFR §56.111 . April 1, 2015 https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=56.111. Accessed June 3, 2016.
- ↵
- Chan S.
- ↵
- Fidler B.
- ↵
- Zannad F,
- Gattis Stough W,
- McMurray JJ,
- et al.
- ↵
- Cannistra SA.
In this issue
Bioethics in Practice: Considerations for Stopping a Clinical Trial Early
Richard E. Deichmann, Marie Krousel-Wood, Joseph Breault
Ochsner Journal Sep 2016, 16 (3) 197-198;